Torbett / Goodsell / Richman The Future of HIV-1 Therapeutics

Resistance Is Futile?
1. Auflage 2015
ISBN: 978-3-319-18518-7
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 389, 254 Seiten, eBook

Reihe: Current Topics in Microbiology and Immunology

This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.

Zielgruppe

Research

Autoren/Hrsg.

Torbett, Bruce E.

Torbett, Bruce

Goodsell, David S.

Richman, Douglas D.

Richman, Douglas

Inhaltsverzeichnis

HIV Therapy Looking Towards the Future.- Computational challenges of structure-based approaches applied to HIV.- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1.- HIV-1 integrase multimerization as a therapeutic target.- Targeting HIV transcription: The quest for a functional cure.- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder.- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy.- The Triple Threat of HIV-1 Protease Inhibitors.- Illustrations of the HIV Life Cycle.